Research programme: anticancer therapeutics - SignalRx Pharmaceuticals
Alternative Names: Delta-PI3K/BRD4 inhibitor - SignalRx; Dual PI3K inhibitors - SignalRx; Pan-PI3K/BRD4 inhibitor - SignalRx; PI3K/BRAF dual inhibitor - SignalRx; PI3K/CDK4-6/BRD4 inhibitor programme; PI3K/CDK4-6/BRD4 inhibitors - SignalRx; PI3K/HDAC dual inhibitor - SignalRx; PI3K/MEK dual inhibitor - SignalRx; PI3K/OTHER dual inhibitor - SignalRx; PI3K/PARP dual inhibitor - SignalRx; SF 2506; SF 2523; SF 2535; SF 2558HA; SF 2626; SF 5000; SRX 2523; SRX 2558; SRX 2626; SRX 3636; SRX 5000; SRX-3207Latest Information Update: 31 Jan 2022
At a glance
- Originator Indiana University School of Medicine
- Developer SignalRx Pharmaceuticals
- Class Pyrones; Small molecules; Thiophenes
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4 protein inhibitors; Cyclin-dependent kinase inhibitors; DNA cytosine 5 methyltransferase inhibitors; Histone deacetylase inhibitors; Isocitrate dehydrogenase 1 inhibitors; Mitogen-activated protein kinase kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto-oncogene protein b-raf inhibitors; Ras signal transduction pathway inhibitors; Wnt protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Dec 2021 Pharmacodynamics data from a preclinical trial in Mantle cell lymphoma (MCL) presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Jul 2018 SignalRx Pharmaceuticals has patent protection for thienopyranones scaffold in USA